Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

3.180 +0.150 (+4.95%)

Streaming Delayed Price Updated: 3:27 PM EDT, Aug 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Preview: Neuronetics's Earnings ↗

March 06, 2023

Via Benzinga

Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives

March 02, 2023

United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients

From Neuronetics

Via GlobeNewswire

Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

February 23, 2023

Company Launches a New Educational Campaign For Providers

From Neuronetics

Via GlobeNewswire

Neuronetics Sponsors the 5th International Brain Stimulation Conference

February 21, 2023

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy

From Neuronetics

Via GlobeNewswire

Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS ↗

January 19, 2023

Via Benzinga

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

February 16, 2023

New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions

From Neuronetics

Via GlobeNewswire

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

February 10, 2023

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

From Neuronetics

Via GlobeNewswire

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

January 17, 2023

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety

From Neuronetics

Via GlobeNewswire

Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay ↗

January 10, 2023

Via Benzinga

Neuronetics's Return On Capital Employed Overview ↗

December 06, 2022

Via Benzinga

Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category

December 05, 2022

NeuroStar’s technology once again recognized as an effective non-drug treatment for patients

From Neuronetics

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 02, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 17, 2022

Via Benzinga

Short Volatility Alert: Neuronetics, Inc. ↗

October 21, 2022

On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went down -1.74% to $2.83. The overall sentiment for STIM has been...

Via Benzinga

Short Volatility Alert: Neuronetics, Inc. ↗

September 23, 2022

On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went up +0.76% to $2.65. The overall sentiment for STIM has been...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations

November 14, 2022

Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy

From Neuronetics

Via GlobeNewswire

Neuronetics Announced as Winner by 2022 Merit Awards for Technology

October 31, 2022

NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health

From Neuronetics

Via GlobeNewswire

Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health

October 25, 2022

Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS

From Neuronetics

Via GlobeNewswire

Despite Competition This Analyst Finds BrainsWay Attractive ↗

August 11, 2022

Via Benzinga

Recap: Neuronetics Q2 Earnings ↗

August 02, 2022

Neuronetics (NASDAQ:STIM) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 27, 2022

Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.

Via Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 19, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 09, 2022

Via Benzinga

Neuronetics's Earnings: A Preview ↗

August 01, 2022

Neuronetics (NASDAQ:STIM) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Neuronetics will...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 20, 2022

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Neuronetics, Inc. - Common Stock (NQ:STIM)

All News about Neuronetics, Inc. - Common Stock